A new study summarizes the best available evidence regarding the risk of heart disease and stroke among people with lupus.
News & Stories
The results of this study indicate that current use of steroids (20 mg/day or more) is perhaps the most significant risk factor for heart disease in individuals with lupus.
The researchers hoped to learn about the relationship among hsCRP, lupus disease activity, and the risk of cardiovascular disease in individuals with lupus.
Metabolic syndrome is marked by increased risk of cardiovascular diseases, so its incidence among people with lupus can indicate risk of cardiovascular disease in lupus patients.
The researchers hoped to learn about the relationship between type I interferon and premature heart disease risk among people with lupus.
Dr. Diane Kamen of the Medical University of South Carolina provides an overview of how lupus can affect the body's organs.
It surprises many people to learn that lung issues are common among people with lupus. Although the underlying connective tissue disease is the root cause of lupus-related lung problems, the exact mechanism differs for each of the most common conditions.
The researchers hoped to learn about the potential effectiveness of assessing heart disease risk in people with lupus by measuring blood pressure and cholesterol levels over multiple time points
The researchers hoped to learn about the safety and efficacy of atorvastatin (Lipitor®) in reducing cholesterol in children with lupus.
People with lupus have an increased risk of heart disease and stroke due to premature hardening of the arteries. The researchers aimed to evaluate how effectively risk for heart disease was being assessed in a population of lupus patients being cared for in Alberta, Canada.
The researchers hoped to learn about lupus-related factors, especially heart disease, that may contribute to the development of depression in people with lupus.
Dr. Joseph McCune of the University of Michigan discusses the role interferon and endothelial cells, which line blood vessels, as possible causes of increased risk of heart attacks and strokes associated with lupus.
Dr. Jill Buyon of the New York University School of Medicine, a leading authority on congenital heart block in neonatal lupus, discusses this rare complication and the next steps in the study of neonatal lupus.
The researchers hoped to learn whether antibodies to cholesterol regulators are associated with disease activity or heart disease in people with lupus.
The researchers hoped to determine the risk of developing blood clots in people with lupus, while factoring in the year of diagnosis and disease severity.
The researchers hoped to identify specific characteristics of lupus patients who develop CHD that differ from those who do not.
The researchers hoped to learn what characteristics of lupus patients might help to predict heart disease.
The researchers wanted to find out whether the amount of leptin, adiponectin, or ghrelin in children with lupus might be different than in children without lupus.
Please join us whether you are a patient, caregiver, or anyone who wants to learn more about lupus.
Our Annual Lupus Symposium in Augusta has moved to March 22, 2014!